Cancer Treatment-Related Bone Disease

被引:29
作者
Brown, Sue A. [1 ]
Guise, Theresa A. [1 ]
机构
[1] Univ Virginia, Dept Med, Charlottesville, VA USA
来源
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION | 2009年 / 19卷 / 01期
基金
美国国家卫生研究院; 美国安德鲁·梅隆基金会;
关键词
cancer; osteoporosis; treatment-related bone loss; hypogonadism; bone metastases; GONADOTROPIN-RELEASING-HORMONE; ANDROGEN-DEPRIVATION THERAPY; VERTEBRAL FRACTURE RISK; RANDOMIZED CONTROLLED-TRIAL; SURGICAL ADJUVANT BREAST; ESTROGEN-RECEPTOR-BETA; YOUNG-ADULT SURVIVORS; MINERAL DENSITY; PROSTATE-CANCER; POSTMENOPAUSAL WOMEN;
D O I
10.1615/CritRevEukarGeneExpr.v19.i1.20
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Bone health may be impaired in many patients being treated for cancer. Primary tumors that reside in or form metastases to bone can result in compromised skeletal integrity. It has also been increasingly recognized that patients undergoing therapies for treatment of cancer are at higher risk of bone loss. These include androgen-deprivation therapy for prostate cancer and aromatase inhibitor therapy for breast cancer, among others. Hypogonadism induced by many of these cancer treatments results in bone loss and increases the risk of osteoporosis and fractures. Progress has been made in identifying the role of oral and intravenous bisphosphonates to prevent bone loss in these patients. This review discusses bone loss associated with cancer treatments, with a focus on breast cancer, prostate cancer, and survivors of childhood malignancies.
引用
收藏
页码:47 / 60
页数:14
相关论文
共 98 条
[1]  
*AM DENT ASS COUNC, 2006, J AM DENT ASSOC, V137, P1144
[2]  
[Anonymous], SEER STAT DAT MORT A
[3]   Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen [J].
Ariazi, Eric A. ;
Leitao, Andrei ;
Oprea, Tudor I. ;
Chen, Bin ;
Louis, Teresa ;
Bertucci, Anne Marie ;
Sharma, Catherine G. N. ;
Gill, Shaun D. ;
Kim, Helen R. ;
Shupp, Heather A. ;
Pyle, Jennifer R. ;
Madrack, Alexis ;
Donato, Anne L. ;
Cheng, Dong ;
Paige, James R. ;
Jordan, V. Craig .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (11) :2817-2827
[4]   Selective toxic effects of tamoxifen on osteoclasts: Comparison with the effects of oestrogen [J].
Arnett, TR ;
Lindsay, R ;
Kilb, JM ;
Moonga, BS ;
Spowage, M ;
Dempster, DW .
JOURNAL OF ENDOCRINOLOGY, 1996, 149 (03) :503-508
[5]   Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells [J].
Arts, J ;
Kuiper, GGJM ;
Janssen, JMMF ;
Gustafsson, JA ;
Lowik, CWGM ;
Pols, HAP ;
VanLeeuwen, JPTM .
ENDOCRINOLOGY, 1997, 138 (11) :5067-5070
[6]   Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial [J].
Bauer, DC ;
Black, DM ;
Garnero, P ;
Hochberg, M ;
Ott, S ;
Orloff, J ;
Thompson, DE ;
Ewing, SK ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1250-1258
[7]   Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].
Black, Dennis M. ;
Delmas, Pierre D. ;
Eastell, Richard ;
Reid, Ian R. ;
Boonen, Steven ;
Cauley, Jane A. ;
Cosman, Felicia ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Mautalen, Carlos ;
Mesenbrink, Peter ;
Hu, Huilin ;
Caminis, John ;
Tong, Karen ;
Rosario-Jansen, Theresa ;
Krasnow, Joel ;
Hue, Trisha F. ;
Sellmeyer, Deborah ;
Eriksen, Erik Fink ;
Cummings, Steven R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822
[8]   Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club [J].
Body, J. J. ;
Bergmann, P. ;
Boonen, S. ;
Boutsen, Y. ;
Devogelaer, J. P. ;
Goemaere, S. ;
Reginster, J. Y. ;
Rozenberg, S. ;
Kaufman, J. M. .
OSTEOPOROSIS INTERNATIONAL, 2007, 18 (11) :1439-1450
[9]  
BRAIDMAN IP, 1995, J BONE MINER RES, V10, P74
[10]  
Brown Sue A, 2007, Curr Osteoporos Rep, V5, P120